When brain tissue injury occurs, S100β is released into the blood, resulting in a significant increase in S100β concentration, and the degree of increase is closely related to the degree of brain injury.
Applicable to various sample types of serum, plasma and whole blood
Rapid detection of single reagent (10 minutes)
Convenient storage and transportation at room temperature
Successfully obtained in the EU CE access certification.
Clinical significance:
S100β is a specific marker for brain injury, which is rapidly released into the blood when brain injury occurs, causing an increase in S100β level. Detecting S100β level in the blood can help doctors to detect brain injury at an early stage, assess the degree of injury and judge the prognosis, which is of great significance in improving the prognosis of patients and reducing the economic burden.
Main clinical applications:
1. Early diagnosis, severity and prognosis assessment of brain injury;
2. Early diagnosis of stroke (cerebral infarction and cerebral hemorrhage), assessment of the degree of brain damage and prognosis;
3. Early diagnosis of central nervous system infections (meningitis), disease assessment and treatment monitoring;
4. Early diagnosis and assessment of brain damage caused by various types of neonatal encephalopathies.
Applicable departments:
Neurology, Neurosurgery, Neonatology, Pediatrics, Geriatrics, Emergency, Cardiology, Surgery,etc
Sample type:serum, plasma, whole blood
Report time:10min
Reference range:<0.2 ng/mL
Storage:4-30℃,sealed and kept away from light and dry
Validity period:18 months
Specifications:25 tests/box,50 tests/box